The wrickkened pathways of FGF23, MEPE and PHEX

被引:101
作者
Rowe, PSN [1 ]
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Periodont, San Antonio, TX 78229 USA
关键词
PHEX; MEPE; FGF23; mineralization; hypophosphatemia; phosphaturic; osteomalacia; rickets;
D O I
10.1177/154411130401500503
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The last 350 years since the publication of the first medical monograph on rickets (old English term wrickken) (Glisson et al., 1651) have seen spectacular advances in our understanding of mineral-homeostasis. Seminal and exciting discoveries have revealed the roles of PTH, vitamin D, and calcitonin in regulating calcium and phosphate, and maintaining healthy teeth and skeleton. However, it is clear that the PTH/Vitamin D axis does not account for the entire picture, and a new bone-renal metabolic milieu has emerged, implicating a novel set of matrix proteins, hormones, and Zn-metallopeptidases. The primary defects in X-linked hypophosphatemic rickets (HYP) and autosomal-dominant hypophosphatemic rickets (ADHR) are now identified as inactivating mutations in a Zn-metalloendopeptidase (PHEX) and activating mutations in fibroblast-growth-factor-23 (FGF23), respectively. In oncogenic hypophosphatemic osteomalacia (OHO), several tumor-expressed proteins (MEPE, FGF23, and FRP-4) have emerged as candidate mediators of the bone-renal pathophysiology. This has stimulated the proposal of a global model that takes into account the remarkable similarities between the inherited diseases (HYP and ADHR) and the tumor-acquired disease OHO. In HYP, loss of PHEX function is proposed to result in an increase in uncleaved full-length FGF23 and/or inappropriate processing of MEPE. In ADHR, a mutation in FGF23 results in resistance to proteolysis by PHEX or other proteases and an increase in half-life of full-length phosphaturic FGF23. In OHO, over-expression of FGF23 and/or MEPE is proposed to result in abnormal renal-phosphate handling and mineralization. Although this model is attractive, many questions remain unanswered, suggesting a more complex picture. The following review will present a global hypothesis that attempts to explain the experimental and clinical observations in HYP, ADHR, and OHO, plus diverse mouse models that include the MEPE null mutant, HYP-PHEX transgenic mouse, and MEPE-PHEX double-null-mutant.
引用
收藏
页码:264 / 281
页数:18
相关论文
共 176 条
[1]   Cathepsin B activity in normal human osteoblast-like cells and human osteoblastic osteosarcoma cells (MG-63): Regulation by interleukin-1 beta and parathyroid hormone [J].
Aisa, MC ;
Rahman, S ;
Senin, U ;
Maggio, D ;
Russell, RGG .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1996, 1290 (01) :29-36
[2]   Cathepsin B in osteoblasts [J].
Aisa, MC ;
Beccari, T ;
Costanzi, E ;
Maggio, D .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2003, 1621 (02) :149-159
[3]  
Allen HC, 2003, J BONE MINER RES, V18, pS170
[4]  
[Anonymous], 1651, TREATISE RICKETS BEI
[5]   MEPE, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone [J].
Argiro, L ;
Desbarats, M ;
Glorieux, FH ;
Ecarot, B .
GENOMICS, 2001, 74 (03) :342-351
[6]   VITAMIN-D-RESISTANT RICKETS ASSOCIATED WITH EPIDERMAL NEVUS SYNDROME - DEMONSTRATION OF A PHOSPHATURIC SUBSTANCE IN DERMAL LESIONS [J].
ASCHINBERG, LC ;
SOLOMON, LM ;
ZEIS, PM ;
JUSTICE, P ;
ROSENTHAL, IM .
JOURNAL OF PEDIATRICS, 1977, 91 (01) :56-60
[7]   Disordered regulation of renal 25-hydroxyvitamin D-1α-hydroxylase gene expression by phosphorus in X-linked hypophosphatemic (Hyp) mice [J].
Azam, N ;
Zhang, MYH ;
Wang, XM ;
Tenenhouse, HS ;
Portale, AA .
ENDOCRINOLOGY, 2003, 144 (08) :3463-3468
[8]   The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency [J].
Bai, XY ;
Miao, DS ;
Goltzman, D ;
Karaplis, AC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (11) :9843-9849
[9]   Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression [J].
Bai, XY ;
Miao, DS ;
Panda, D ;
Grady, S ;
McKee, MD ;
Goltzman, D ;
Karaplis, AC .
MOLECULAR ENDOCRINOLOGY, 2002, 16 (12) :2913-2925
[10]  
BARRETT AJ, 1995, METHOD ENZYMOL, V248, P1